21 CFR § 316.50 Orphan Drugs

§ 316.50 Guidance documents.

Current through Sep 8, 2026 · Read all of Part 316

FDA's Office of Orphan Products Development will maintain and make publicly available a list of guidance documents that apply to the regulations in this part. The list is maintained on the Internet and is published annually in the Federal Register. A request for a copy of the list should be directed to the Office of Orphan Products Development, Food and Drug Administration, Bldg. 32, rm. 5271, 10903 New Hampshire Ave., Silver Spring, MD 20993.

[78 FR 35135, June 12, 2013]

← § 316.40 Treatment use of a designated orphan drug.§ 316.52 Availability for public disclosure of data and information in requests and applications. →